PROTAGENIC THERAPEUTICS INC (PTIX)

Stay updated with the stocks that are on the move in today's after-hours session.

As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million

PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q2 2024

Protagenic Therapeutics just reported results for the second quarter of 2024.

PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Protagenic Therapeutics (NASDAQ:PTIX) just reported results for the second quar...

PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Protagenic Therapeutics (NASDAQ:PTIX) just reported results for the first quart...

PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q1 2024

Protagenic Therapeutics just reported results for the first quarter of 2024.

Protagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric Disorders

Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial

Protagenic Therapeutics’ Innovative Peptide PT00114 to be Highlighted at Boston Summit

PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q4 2023

Protagenic Therapeutics just reported results for the fourth quarter of 2023.

PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Protagenic Therapeutics (NASDAQ:PTIX) just reported results for the fourth quar...

Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results

Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders

Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call

Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice

Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders

Protagenic Therapeutics Initiates Phase I/IIa Clinical Trial for Groundbreaking Brain Peptide PT00114

Protagenic Therapeutics says board approved 1-for-4 reverse stock split (NASDAQ:PTIX)

Protagenic Therapeutics (PTIX) on Wednesday announced it has approved a 1-for-4 reverse stock split of the company's issued and outstanding common stock.

Protagenic Therapeutics to Effect 1-for-4 Reverse Stock Split